UNSPSC 51241534: Hypromellose/naphazoline

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP800. This VA Drug Class (OP800) classifies this compound as belonging to the group DECONGESTANTS, TOPICAL OPHTHALMIC.

UNSPSC 51241534 Hypromellose/naphazoline is a Commodity code covering ophthalmic pharmaceutical products that state and local governments procure as part of broader multi-source generic medication and over-the-counter product programs. The code captures individual active pharmaceutical ingredients and formulations distributed through state health systems, correctional facilities, local health departments, and other government healthcare operations. Recent solicitations show state and local buying focused on establishing tiered pharmaceutical supply contracts with manufacturers capable of meeting FDA compliance, current Good Manufacturing Practices certification, and Drug Supply Chain Security Act requirements, delivered through authorized wholesale distribution networks rather than direct procurement. Issuing bodies include state health and procurement departments managing cooperative purchasing alliances and their member jurisdictions, spanning state agencies, counties, municipalities, and health districts across multiple participating states.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026 seeking manufacturers of generic pharmaceuticals and OTC products for distribution across participating state and local facilities in Minnesota, Oregon, and other member jurisdictions. The RFP due date was March 26, 2026, with products required to be marketplace-available by May 15, 2026 and resulting contracts effective July 1, 2026. Vendors must maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen/Cencara, Cardinal Health 110 or 112, or Morris & Dickson), carry $5 million in commercial general liability insurance and $2 million in network security and professional liability coverage, and accept a 3 percent administrative fee on all contract purchases. Award evaluations weight price competitiveness at 75 percent, with remaining points distributed across fixed pricing, administrative compliance, EDI capability, and fee acceptance. MMCAP reserves multi-award authority based on therapeutic need and member-specific requirements, with contract terms of two years for new vendors and alignment with existing agreements through June 30, 2028 for incumbent responders.